wire - news in brief
Category
Results 51 - 100 of 370.
Roche announces FDA grants Venclexta accelerated approval for people with newly-diagnosed acute myeloid leukaemia or those who are ineligible for intensive induction chemotherapy
Approval based on two studies that showed durable remissions in people with newly-diagnosed acute myeloid leukaemia, who are age 75 years or older, or for those ineligible for intensive induction che
Approval based on two studies that showed durable remissions in people with newly-diagnosed acute myeloid leukaemia, who are age 75 years or older, or for those ineligible for intensive induction che
Industry representatives met at Empa's Thun campus last week to get information on the latest high-tech trends in industrial coatings. The partnership with the Hightech Zentrum Aargau strengthens the transfer of knowledge from research to companies. The joint technology briefing of Empa and the Hightech Zentrum Aargau on 14 November in Thun was fully booked with 80 participants.
Sandoz and Pear Therapeutics announce launch of reSET for treatment of patients with Substance Use Disorder
ReSET is the first and only FDA-authorized prescription digital therapeutic for Substance Use Disorder (SUD) Adding reSET to outpatient therapy significantly improved abstinence in substances of abus
ReSET is the first and only FDA-authorized prescription digital therapeutic for Substance Use Disorder (SUD) Adding reSET to outpatient therapy significantly improved abstinence in substances of abus
Addressing the Territorial Dimensions in Party-based Populism
Parution d'un numéro spécial de la revue Comparative European Politics consacré aux partis régionalistes populistes et édité par Reinhard Heinisch (Universität Salzburg), Emanuele Massetti (University of Surrey) et Oscar Mazzoleni (Université de Lausanne).
Parution d'un numéro spécial de la revue Comparative European Politics consacré aux partis régionalistes populistes et édité par Reinhard Heinisch (Universität Salzburg), Emanuele Massetti (University of Surrey) et Oscar Mazzoleni (Université de Lausanne).
The European Medicines Agency's Committee for Medicinal Products for Human Use has adopted a positive opinion of fexinidazole, the first all-oral treatment that has been shown to be efficacious for both stages of sleeping sickness.
In order to examine how synaptic inputs to individual neurons are organized in a distributed memory network, researchers from the Friedrich group performed electrophysiological recordings in the zebrafish homolog of the olfactory cortex. They found that large excitatory inputs were paired with large inhibitory inputs, which may seem counterintuitive because inhibition cancels excitation.
FDA approves Novartis drug Promacta for first-line SAA and grants Breakthrough Therapy designation for additional new indication
Promacta receives FDA approval for first-line treatment of severe aplastic anemia (SAA) and Breakthrough Therapy designation for low platelet counts in people exposed to radiation Approval based on compelling benefit established through complete response rates among SAA patients when Promacta is added to standard immunosuppressive therapy relative to historic information on that therapy alone Promacta is the first new treatment in decades fo
Promacta receives FDA approval for first-line treatment of severe aplastic anemia (SAA) and Breakthrough Therapy designation for low platelet counts in people exposed to radiation Approval based on compelling benefit established through complete response rates among SAA patients when Promacta is added to standard immunosuppressive therapy relative to historic information on that therapy alone Promacta is the first new treatment in decades fo
Novartis receives positive CHMP opinion to expand Kisqali combination therapy to all women with HR+/HER2- locally advanced or metastatic breast cancer
Novartis receives positive CHMP opinion to expand Kisqali combination therapy to all women with HR+/HER2- locally advanced or metastatic breast cancer Kisqali is the CDK4/6 inhibitor with the largest body of first-line evidence demonstrating consistent, superior and sustained efficacy vs.
Novartis receives positive CHMP opinion to expand Kisqali combination therapy to all women with HR+/HER2- locally advanced or metastatic breast cancer Kisqali is the CDK4/6 inhibitor with the largest body of first-line evidence demonstrating consistent, superior and sustained efficacy vs.
The Swiss sportswear manufacturer KJUS presented the world's first ski jacket with an integrated electronic user-controlled membrane on November 15.
FDA grants priority review to Roche’s Tecentriq in combination with Abraxane for the initial treatment of people with PD-L1-positive, metastatic triple-negative breast cancer
Triple-negative breast cancer is an aggressive disease, with high unmet medical need If approved, this Tecentriq (atezolizumab) combination would be the first cancer immunotherapy regimen for the treatment of PD-L1-positive, metastatic triple-negative breast cancer Roche today announced the US Food and Drug Administration (FDA) has accepted the company's supplemental Biologics License Application (sBLA) and granted Priority Review for Tecentriq
Triple-negative breast cancer is an aggressive disease, with high unmet medical need If approved, this Tecentriq (atezolizumab) combination would be the first cancer immunotherapy regimen for the treatment of PD-L1-positive, metastatic triple-negative breast cancer Roche today announced the US Food and Drug Administration (FDA) has accepted the company's supplemental Biologics License Application (sBLA) and granted Priority Review for Tecentriq
New Novartis study supports Entresto as foundational HFrEF therapy and in-hospital initiation in appropriate stabilized heart failure patients
Entresto (sacubitril/valsartan) outperformed commonly used heart failure medicine enalapril in landmark study; delivered significantly greater and more rapid reductions in an established biomarker fo
Entresto (sacubitril/valsartan) outperformed commonly used heart failure medicine enalapril in landmark study; delivered significantly greater and more rapid reductions in an established biomarker fo
Federal authorities launch a campaign to promote appropriate use of antibiotics
Bern, 09.11.2018 - Maintaining the effectiveness of antibiotics for humans and animals, and combating resistance - these are the two main objectives of the national Strategy on Antibiot
Bern, 09.11.2018 - Maintaining the effectiveness of antibiotics for humans and animals, and combating resistance - these are the two main objectives of the national Strategy on Antibiot
For the past 15 years, EPFL's Urban Sociology Laboratory has been showing students and researchers the value of incorporating social-science related concepts into engineering and architecture.
A small lab-grown diamond measuring a few millimeters per side could one day enable civilian drones to be recharged in mid-flight through a laser. Thanks to the diamond, the laser beam can remain strong enough over a long distance to recharge photovoltaic cells on the drones' surface. This system, which poses no threat to human health, is being developed by EPFL spin-off LakeDiamond.
This year's Swiss Aerosol Award goes to Maria Muñoz. The Empa researcher investigated the emission behavior of so-called GDI engines (gasoline-direct injection).
Novartis R&D update highlights industry leading development pipeline including potential blockbusters and advanced therapy platforms
26 potential blockbusters in confirmatory development. 13 projects in clinical development across Cell, Gene & Radioligand therapies.
26 potential blockbusters in confirmatory development. 13 projects in clinical development across Cell, Gene & Radioligand therapies.
Novartis data at ASH and SABCS show strength of pipeline and portfolio in hematology and oncology
Additional analysis from pivotal Phase III SOLAR-1 clinical trial studying investigational alpha-specific PI3K inhibitor BYL719 (alpelisib) and fulvestrant in patients with PIK3CA-mutated HR+/HER2- a
Additional analysis from pivotal Phase III SOLAR-1 clinical trial studying investigational alpha-specific PI3K inhibitor BYL719 (alpelisib) and fulvestrant in patients with PIK3CA-mutated HR+/HER2- a
Companies increasingly focusing on product improvement and process optimisation
Bern, 02.11.2018 - It seems to have become more difficult and expensive for companies in Switzerland to invest in developing new, innovative products.
Bern, 02.11.2018 - It seems to have become more difficult and expensive for companies in Switzerland to invest in developing new, innovative products.
The Wyss Foundation announced yesterday that it will begin a global conservation campaign. On a related note, they also announced that they will be working on a year-long pilot project in Kenya and Peru, together with the University of Bern.
Andrea Ablasser wins the 2018 National Latsis Prize
The medical researcher and EPFL professor Andrea Ablasser , who studies how cells defend themselves against viral and bacterial attacks, has won the 2018 National Latsis Prize in recognition of her excellent research work on immunity.
The medical researcher and EPFL professor Andrea Ablasser , who studies how cells defend themselves against viral and bacterial attacks, has won the 2018 National Latsis Prize in recognition of her excellent research work on immunity.
Lifting the mask
Laughter is the best medicine, says medical research.
Laughter is the best medicine, says medical research.
The medical researcher and EPFL professor Andrea Ablasser studies how cells defend themselves against viral and bacterial attacks.
Roche announces EU approval of Venclyxto plus MabThera for people with previously treated chronic lymphocytic leukaemia
Approval is based on randomised phase III MURANO study showing that fixed duration of treatment with Venclyxto plus MabThera is well tolerated and reduced risk of disease progression or death by 83%
Approval is based on randomised phase III MURANO study showing that fixed duration of treatment with Venclyxto plus MabThera is well tolerated and reduced risk of disease progression or death by 83%